Production (Stage)
Oramed Pharmaceuticals Inc.
ORMP
$2.22
$0.073.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | -- | 0.00 | 0.00 | 674.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | -- | 0.00 | 0.00 | 674.00K |
| Cost of Revenue | 1.99M | -- | -- | -- | -- |
| Gross Profit | 13.00K | -- | 0.00 | 0.00 | 674.00K |
| SG&A Expenses | 6.98M | 6.46M | 6.43M | 7.52M | 8.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.32M | 12.78M | 13.06M | 12.87M | 14.20M |
| Operating Income | -14.32M | -12.78M | -13.06M | -12.87M | -13.52M |
| Income Before Tax | -24.51M | -15.92M | 7.16M | 22.38M | 10.23M |
| Income Tax Expenses | 3.77M | 3.18M | 2.77M | 1.63M | -- |
| Earnings from Continuing Operations | -28.28 | -19.10 | 4.39 | 20.75 | 10.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 41.00K | 43.00K | 73.00K | 112.00K | 223.00K |
| Net Income | -28.24M | -19.06M | 4.47M | 20.86M | 10.46M |
| EBIT | -14.32M | -12.78M | -13.06M | -12.87M | -13.52M |
| EBITDA | -14.15M | -12.59M | -12.85M | -12.65M | -13.31M |
| EPS Basic | -0.69 | -0.47 | 0.11 | 0.51 | 0.26 |
| Normalized Basic EPS | -0.21 | -0.18 | -0.19 | 0.04 | -0.14 |
| EPS Diluted | -0.71 | -0.49 | 0.10 | 0.50 | 0.25 |
| Normalized Diluted EPS | -0.21 | -0.19 | -0.20 | 0.04 | -0.14 |
| Average Basic Shares Outstanding | 163.75M | 163.36M | 163.21M | 162.76M | 162.03M |
| Average Diluted Shares Outstanding | 164.38M | 164.72M | 165.58M | 165.13M | 163.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |